Disease | non-alcoholic fatty liver disease |
Symptom | C0239946|liver fibrosis |
Sentences | 20 |
PubMedID- 23626613 | furthermore, the risk of thrombosis in patients with non-alcoholic fatty liver disease was associated with advanced liver fibrosis and nonalcoholic steatohepatitis. |
PubMedID- 26494963 | liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. |
PubMedID- 23710314 | Background/aims: the bard score is a model to detect advanced liver fibrosis in nonalcoholic fatty liver disease (nafld) patients. |
PubMedID- 23258240 | Predictors of liver fibrosis in patients with non-alcoholic fatty liver disease. |
PubMedID- 25326152 | Background: accurately evaluating liver fibrosis in patients with non-alcoholic fatty liver disease (nafld) is important for identifying those who may develop complications. |
PubMedID- 19931264 | Hfe genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. |
PubMedID- 24628717 | Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: proceed with caution. |
PubMedID- 22168074 | Elastography efficiency in the liver fibrosis determination in patients with nonalcoholic fatty liver disease. |
PubMedID- 22140659 | Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. |
PubMedID- 22045426 | Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. |
PubMedID- 20373368 | Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. |
PubMedID- 24798049 | The combination of liver stiffness measurement and nafld fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. |
PubMedID- 20526777 | Objective: transient elastography (te) has shown promising results for the staging of liver fibrosis in patients with non-alcoholic fatty liver disease (nafld) and steatohepatitis (nash) with the limitation that 25% of obese patients cannot be examined with the standard te probe. |
PubMedID- 25836944 | Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. |
PubMedID- 25608776 | The aim of our pilot study was to assess the clinical performance of the apparent diffusion coefficient (adc) of liver parenchyma for the assessment of liver fibrosis in patients with non-alcoholic fatty liver disease (nafld). |
PubMedID- 22087183 | The major finding of their study was that the apri also had an acceptable accuracy for the assessment of liver fibrosis in patients with nonalcoholic fatty liver disease (nafld), tending to increase with the degree of fibrosis. |
PubMedID- 24342745 | Background & aims: series studies have associated increased serum levels of ferritin with liver fibrosis in patients with nonalcoholic fatty liver disease. |
PubMedID- 20540856 | Conclusions: both timp-1 and -2 may reflect the state of liver fibrosis in children with nonalcoholic fatty liver disease, and serum timp-1 appears to be more reliable. |
PubMedID- 23480804 | liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. |
PubMedID- 26049707 | Objective: the purpose of this study was to noninvasively estimate disease activity and liver fibrosis in patients with nonalcoholic fatty liver disease (nafld) using anthropometric and biochemical characteristics and the c-methionine breath test (mebt). |
Page: 1